Skip to main content

Effects of Histidine-Tag on Recombinant Human Cytochrome P450 3A5 Catalytic Activity in Reconstitution Systems

Buy Article:

$68.00 + tax (Refund Policy)

Cytochrome P450 (P450) plays an important role for oxidation of a variety of chemicals. Human P450 3A5 is recognized as the secondly most important enzymes among P450 3A subfamily, with some differences in substrate specificity, catalytic activity, and regioselectivity of P450 3A4. Because addition of histidine-tag to microsomal P450s is universally used for recombinant protein purifications, purified P450 3A4 protein is commercially available, but P450 3A5 is not at present. In the present study, although catalytic activity of purified P450 3A5 expressed using the original plasmid from bacterial membranes was observed in reconstitution systems containing NADPH-P450 reductase, cytochrome b5, and phospholipids, a histidine-tagged P450 3A5 protein did not show any detectable midazolam hydroxylation activities in the same reconstitution systems. From the docking simulation of midazolam into a P450 3A5 homology model based on the published P450 3A4 structure, it was supported that midazolam could not easily access to the center of the heme of histidine-tagged P450 3A5, with the high interaction energy compared with the original P450 3A5. In conclusion, these results suggest that the histidine-tagged system would be non-applicable for P450 3A5 function.





Keywords: CYP3A5; E. coli membranes; histidine; human; reconstitution system

Document Type: Research Article

Publication date: 01 December 2009

More about this publication?
  • Drug Metabolism Letters publishes short papers on major advances in all areas of drug metabolism and disposition. The emphasis will be on publishing quality papers very rapidly. Letters will be processed rapidly by taking full advantage of the Internet technology for both the submission and review of manuscripts. The journal covers the following areas:

    In vitro systems including CYP-450; enzyme induction and inhibition; drug-drug interactions and enzyme kinetics; pharmacokinetics, toxicokinetics, species scaling and extrapolations; P-glycoprotein and transport carriers; target organ toxicity and interindividual variability; drug metabolism and disposition studies; extrahepatic metabolism; phase I and phase II metabolism; recent developments for the identification of drug metabolites, reactive intermediate and glutathione conjugates.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content